Ozarelix (D-63153) / COSCIENS Biopharma, Nippon Kayaku, Assertio - LARVOL DELTA

Aggregation Behavior of Structurally Similar Therapeutic Peptides Investigated by H NMR and All-Atom Molecular Dynamics Simulations. (PubMed, Mol Pharm) - "A series of structurally similar, pharmaceutically relevant peptides with known differences in aggregation behavior (D-Phe-GnRH, ozarelix, cetrorelix, and degarelix) were investigated. The AA-MD simulations also provided molecular-level insights into aggregation dynamics, aggregation pathways, and the influence of different structural elements on peptide aggregation propensity and intermolecular interactions within the aggregates. Taken together, the findings from this study illustrate that H NMR and AA-MD simulations can be useful, complementary tools in early evaluation of aggregation propensity and formulation development for peptide drugs."

Journal

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH) (clinicaltrials.gov) - P2; N=28; Terminated; Sponsor: Spectrum Pharmaceuticals, Inc; N=860 ➔ 28

Clinical • Enrollment change • Benign Prostatic Hyperplasia

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate (clinicaltrials.gov) - P2; N=74; Completed; Sponsor: Spectrum Pharmaceuticals, Inc; Phase classification: P2/3 ➔ P2

Clinical • Phase classification • Benign Prostatic Hyperplasia